Thomas Le Bihan, Cathryn H. S. Driver, Thomas Ebenhan, Nathalie Le Bris, Jan Rijn Zeevaart and Raphaël Tripier
GluCAB-2Mal is working on the principle of tumor targeting through the Enhanced Permeability and Retention (EPR) effect as well as glucose metabolism. It was radiolabelled with 64Cu (99%), proved to be highly stable in serum and with immediate binding to serum proteins. [64Cu]Cu-GluCAB-2Mal was studied for in vivo experiments i.e. microPET/CT imaging and biodistribution analysis in an allograft E0771 breast cancer mouse model.